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1. Introduction 
Non-insulin-dependent diabetes mellitus is one of the most widely spread and severe 
disorder currently, being the fourth mortality reason, globally. The number of patients 
suffering from diabetes mellitus was reported to be over 200 million people worldwide, a 
big part of it being NIDDM patients. Divalent cations of macro and trace elements play 
important roles in human body.  
Magnesium (Mg) is an important divalent cation mostly localized intracellular. 
Zinc (Zn) is one of the most important trace elements in the body. It is required for over 300 
different cellular processes, including enzyme activity, protein synthesis and intracellular 
signaling [1]. It is involved in homeostasis, in immune responses, in oxidative stress, in 
apoptosis and in ageing [2]. 
Copper (Cu) is an essential trace element, capable of fluctuating between the oxidized Cu2+ and 
the reduced Cu+ state, being co-factor for many enzymes. This divalent cation is involved in 
SOD activity. Copper has the capacity to form covalent bounds and it takes part in many redox 
processes. Copper ions are involved in generation of reactive oxygen species through Fenton 
reaction, having a pro-oxidant action. Moreover, the deficiencies and the excess of Cu are 
associated with specific clinical manifestations [3]. Diabetes mellitus is a chronic metabolic 
disorder associated with the increased free radical production leading to oxidative damage, 
and many of the pathological effects of copper overload are consistent with an oxidative 
damage to membranes or macromolecules. Variation in the concentrations of those divalent 
cations is important to oxidative stress to which the diabetic patient’s organism is submitted. 
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Today there is an extensive range of anti-diabetic drugs for oral intake for type 2 diabetes. 
The main classes are different in their mechanism of action, safety profiles and tolerability 
and include: agents that stimulate insulin secretion (sulphonylureas), agents that reduce 
hepatic glucose production (biguanides), glinides, agents that delay digestion and 
absorption of carbohydrate (alpha-glucosidase inhibitors) or improve insulin action 
(thiazolidinediones).  
Metformin is one of the most used drug in the treatment of NIDDM . This drug does not 
promote weight gain and has beneficial effects on several cardiovascular risk factors. 
Metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. 
[4] This substance is the drug of choice and should be initiated immediately after diabetes is 
diagnosed. If monotherapy does not provide satisfactory glucose control, other oral anti-
diabetic agents or insulin are added in combination. In the metabolic syndrome, metformin 
is also the drug of choice. [5] The action of oral anti-diabetics at the level of vascular 
endothelium and the cardio-protective effect play an increasing role in the choice of anti-
diabetic agents. 
2. The aim of the study 
This research was performed to determine the plasmatic, cellular and urinary concentration 
of certain divalent cations in newly diagnosed NIDDM patients that have never received 
any kind of oral anti-diabetic drugs or insulin and at the same time to determine the 
metformin effect on intracellular magnesium concentration, plasma and urinary 
concentrations of different divalent cations. 
Our study surveyed the status of magnesium, copper, zinc, calcium in plasma and urine and 
erythrocyte magnesium, influenced by metformin administration, in NIDDM adult patients 
from the moment of diagnosis and during the therapy with oral anti-diabetic medication. 
At the same time, other biochemical parameters were determined, necessary to evaluate the 
carbohydrate metabolism and lipidic profile and different correlations were established 
between carbohydrate-lipidic metabolic parameters and plasma, urinary and cellular 
divalent cations concentrations. 
3. Material and methods 
The study was performed on a group of 30 adult patients with NIDDM, 18 males and 12 
females, with ages between 30 and 60 years ( interval of 30-40y: 2 patients, 40-50y: 13 
patients and 50-60y: 15 patients) that have never received any anti-diabetic medication, and 
a control group of 17 healthy subjects.  
Patients with NIDDM, diagnosed in the Diabetes, Nutrition and Metabolic Diseases Clinic 
of Clinical County Emergency Hospital Constanta, according to the European Guide for 
Diabetes [6] were administered metformin (SioforR, Berlin Chemie) 500 mg x 2 times /day, 
together with a diet list comprising approximately 320 mg/day magnesium. 
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Subject selection criteria were: NIDDM adult subjects with absence of any previous 
treatment with oral anti-diabetic agents, insulin or trace elements to follow medical therapy 
with metformin yet without co-administration of other oral anti-diabetic agents. Non-
including criteria were: pregnancy, hepatic cirrhosis, renal failure, psychosis, diuretic 
therapy, chronic diarrhea. An individual investigation protocol was elaborated containing 
the principal parameters to be investigated, and the study was performed according to the 
rules of clinical studies of the European Union, with the approval of the Ethical Committee 
of the University, and informed written consent was obtained from each subject included 
into the study. 
The measured parameters were: glucose, HbA1c, creatinine, HDL, LDL, cholesterol, 
triglycerides, magnesium, copper, zinc and calcium in blood plasma; intra-erythrocyte 
magnesium; magnesium, copper, zinc and calcium concentration inurine/24 hours. 
Measurements were initially made before the administration of metformin, and after 3 
months of therapy. 
Material and methods: measurements were made by means of a Rx Daytona analyzer, a 
compact fully automated clinical analyzer, produced by Randox LTD Laboratories, UK, also 
used for all the other quantitative analyses, except erythrocyte magnesium. 
Rx Daytona is an automated clinical chemistry analyzer with specific analyzer software, 
being an “in vitro diagnosis medical device” in compliance with IVD Directive and the EMC 
Directive of EU. The analyzer is recommended for general chemistry as photometric assay, 
immunology (latex reagents), with analysis methods: 1 point, 2 point end, 1 point rate, 2 
point rate, and calibration options such as: factor, linear, Log Logit, exponential, spline, 
point to point; sample types for analysis can be: serum, plasma, urine, CSF, supernatants 
whole blood. 
Methods of measurements for plasma divalent cations: venous blood samples from the 
subjects were collected in the morning after an overnight fast, into special blood collection 
tubes (vacutainer). There were used blood vacutainers with sodium heparin (green cup) for 
the measurement of zinc, copper, magnesium in plasma. 
Plasma concentrations were determined through spectrophotometric method, using Randox 
kits, with plasma reference materials and controls, normal and abnormal level. 
Measurements were made by means of a Rx Daytona analyzer. Atomic absorption 
spectrophotometry (AAS) is the reference method for the determination of the cations in 
biological specimens, but it is not a usual method in clinical laboratories. The colorimetric 
methods used in clinical laboratories, especially for magnesium which is widely used, are 
fairly accurate and precise with a good correlation (r= 0.986) compared to AAS. Heparinized 
samples were centrifuged at 1500 g for 10 min to separate plasma from erythrocytes. Plasma 
was used for estimation of extracellular magnesium (without deproteinization), while 
trichloroacetic acid was added to precipitate proteins, the supernatant being used for 
analysis of zinc and copper. The measurements were initially made before the 
administration of metformin, and after 3 months of therapy. 
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Methods of measurements for urinary divalent cations: urine samples were collected in 
sterile, chemically clean universal containers, 30 ml, from urine / 24 h, the volume being 
measured. The samples were prepared in 30 minutes after collection, urine been transferred 
in test tubes. For estimation of calcium and magnesium the samples were used directly, for 
zinc and copper trichloroacetic acid was added to precipitate proteins. 
The concentration of cations/24 h, was determined through spectrophotometric method, by 
means of Rx Daytona analyzer. 
Methods of measurements for erythrocyte magnesium: blood vacutainers with sodium 
heparin (green cup) were used. Heparinized samples were centrifuged at 1500 g for 10 min 
to separate plasma from erythrocytes. The determination of erythrocyte magnesium was 
made using the colorimetric assay with xylidyl blue, a metallochromic dye,[3,4] after the 
lysis of 100 μl erythrocytes with 1500 μl double-distilled water, and deproteinization with 
200 μl 0.3 mol/l Na2WO4 and 200 μl 0.35 mol/l H2SO4. The trade kit used was Human, the 
blue magnesium xylidyl complex, was measured at 532 nm, using a spectrophotometer (AR- 
Cromaline, Barcelona, Spain). Standard solutions were used along with blank solutions 
(1000μl working solution, 160 μl double-distilled water, 20 μl 0.3 mol/l Na2WO4 and 20 μl 
0.35 mol/l H2SO4), for every analytic procedure. [7] 
Methods for statistical analysis: the statistical significance and the correlations between 
plasmatic concentrations of the divalent cations and erythrocyte magnesium with glycemia, 
HbA1c, cholesterol, triglycerides, HDL were determined. 
The results are expressed as means ± S.D. Differences between groups were examined using 
the unpaired Student’s t-test, and considered statistically significant at p<0.05, differences in 
the group were examined using the paired Student’s test, considered statistically significant 
at p<0.05, and to asses possible relationships between different variables, Pearson’s 
correlation coefficient (r) was used. The statistical analyses were done using the SPSS for 
Windows 12.00. 
4. Results 
Plasma total magnesium level is reduced in NIDDM patients before treatment compared to 
healthy controls (1.95 ± 0.19 vs. 2.20 ±0.18 mg/dl, p< 0.001) and determination of plasma 
magnesium concentration after 3 months treatment with metformin revealed that there were 
not significant differences compared to the initial moment (M = 1.96, SD = 0.10 vs. M = 1.95, 
SD = 0.19, p= 0.735) and when compared with control group there are significant differences 
(M = 1.96, SD =0.105 vs M = 2.21, SD = 0.193, p< 0.001). Fig 1 
Plasma zinc in NIDDM patients: data reveal significant differences in the NIDDM group 
versus the control group, for plasma zinc (67.56 ± 6.21 vs. 98.41± 20.47 μg/dl, p<0.001) and 
determination after 3 months treatment with metformin revealed that there were not 
significant differences compared to the initial moment (M = 64.25, SD = 5.59 vs. M = 67.56, 
SD = 6.21 vs. p=0.067) and when compared with control group there are still significant 
differences (M=64.25, SD = 5.60 vs. M = 101.65, SD = 23.14 , p< 0,001). Fig 2 
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Figure 1. Plasma magnesium concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
 
Figure 2. Plasma zinc concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
Plasma copper in NIDDM patients is increased when compared to healthy subjects 
(M=111.91+/-20.98 vs. M= 96.33+/- 8.56 μg/dl, p<0.001) Treatment with metformin did not 
modify significantly the concentration of this cation (M = 111.91, SD = 20.98 μg/dl vs. M 
=110.91, SD = 18.61 p= 0.413) and compared to control group there are not significant 
differences (M =110.08, SD = 18.61 μg/dl vs. M = 101.23, SD =21.73, p=0.147) (Fig 3) but when 
we compare those levels between the metabolic uncontrolled patients group (8 patients 
were prescribed another anti-diabetic drug after 3 months therapy with metformin) and the 
ones with metabolic control of metformin treatment (n=22) we see that there are significant 
differences (M = 127.22, SD = 22.64 μg/dl vs. M = 103.85, SD = 12.43, p= 0.023). Fig. 4 
Plasma calcium in NIDDM patients before medication revealed non-significant differences 
when compared to healthy subjects. (M= 8.93± 0.33 mg/dl vs. 8.87 ± 0.35, p= 0.300) Treatment 
with metformin did not modify significantly the concentration of this cation (M = 8.987, SD = 
0.44 mg/dl vs. M = 8.983, p=0.147) and compared to control group after 3 months of 
treatment there were not significant differences: (M = 8.98, SD = 0.44 mg/dl vs. M = 8.92, SD = 
0.43, p= 0.633). 
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Figure 3. Plasma copper concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
 
 
Figure 4. Plasma copper concentrations in metabolic uncontrolled patients by metformin vs metabolic 
controlled patients (NS – non-significant, * - p<0.05, ** - p<0.01) 
Data about intra-erythrocyte total magnesium concentration in NIDDM patients has 
revealed a decreased concentration of erythrocyte magnesium in NIDDM patients before 
medication, when compared to healthy subjects (5.09 ± 0.63 vs. 6.38 ± 0.75 mg/dl, p< 0.001) 
and treatment with metformin has revealed that there were significant differences compared 
to the moment before medication: (M = 5.75 SD = 0.61 mg/dl vs. M = 5.09, SD =0.63, p<0.001) 
but compared to the control group the differences are still significant: (M = 5.75 SD =0.61 vs. 
M = 6.39 SD = 0.72, p=0.002) Fig 5  
Urinary magnesium is increased in NIDDM patients before medication, when compared to 
healthy subjects (237.28±34.51 vs. 126.25±38.82 mg/24h p<0.001) and in NIDDM patients 
treated with metformin there were significant differences compared to the moment before 
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medication: (M = 198.27 SD = 27.07 mg/24 h vs. M = 237.28, SD = 34.51 mg/24h p< 0.001), but 
compared with control group the differences are still significant M = 198.27 SD = 27.07 
mg/24h vs. M = 138.39, SD = 41.37 p< 0,001). Fig 6 
 
Figure 5. Intraerhytrocyte total magnesium concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
 
Figure 6. Urinary magnesium concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
Urinary zinc in NIDDM patients is increased before medication, when compared to healthy 
subjects (1347,54 ±158,24 vs. 851,65± 209,75 μg/24 h, p< 0,001) and after 3 months of 
medication our data has revealed that there were not significant differences compared to the 
moment before medication: (M = 1339,63 SD= 160,22 μg/24 h vs. M = 1347,54, SD = 158,24, 
p=0,530 ) and compared to the control group the differences are still significant (M = 1339,63, 
SD = 160,22 μg/24 h vs. M =880,76,SD = 186,38,p<0,001). Fig 7 
Urinary copper in NIDDM patients is increased before medication, when compared to 
healthy subjects (51,70±23,79 vs. 36,00±11,70 μg/24h, p<0,05) and after medication data has 
revealed that there were not significant differences compared to the moment before 
medication: (M=51,705 SD = 22,13vs 53,35 μg/24 h , SD = 23,79, p= 0,301) and compared to 
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the control group there are significant differences (M = 51,70, SD = 22,13 μg/24 h vs. M = 
36,00, SD = 11,66 p= 0,009). Fig 8  
 
Figure 7. Urinary zinc concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
 
 
Figure 8. Urinary copper concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
Urinary calcium concentration in NIDDM patients is increased before medication, 
(309,23±58,41 vs. 201,51±62,13 mg/24h, p<0,001) and in NIDDM patients treated with 
metformin our data has revealed that there were significant differences compared to the 
moment before medication (M = 287,09 SD = 55,39 mg/24h vs. M = 309,23, SD = 58,41, p< 
0,001) and compared to the control group: M = 287,09, SD = 55,39 mg/24h vs. M = 216,9 SD = 
57,25 mg/24h, p< 0,001) Fig 9 
The following correlations were obvious in metformin treated patients after 3 months: 
negative correlation between plasma total magnesium and glucose plasma level, positive 
correlation between plasma total magnesium and HbA1c, positive correlation between 
plasma Cu2+ - glucose plasma level and HbA1c, positive correlation between plasma Cu2+ - 
cholesterol plasma level and triglycerides, positive correlation between plasma Zn2+ and 
glucose plasma level, negative correlation between erythrocyte total magnesium - glucose 
plasma level and HbA1c, positive correlation between HbA1c and urinary Zn2+ 
concentration. 
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Figure 9. Urinary calcium concentrations (NS – non-significant, * - p<0.05, ** - p<0.01) 
5. Discussions 
The plasma magnesium level is reduced in diabetes mellitus. Our data reveals significant 
differences in NIDDM group versus the control group, for plasma magnesium (Fig. 1)  
In accordance with other authors our data reveals the existence of plasma low total 
magnesium level in patients with NIDDM when compared to healthy adults. [8] 
Hypomagnesaemia is also involved in NIDDM pathogenesis and its complications. Both 
experimental and clinical studies suggest that hypermagnesemia may be the major factor 
involved in diabetes hypomagnesaemia. A specific renal tubular magnesium defect in 
diabetes together with the increased osmotic diuresis is responsible for large magnesium 
losses.[9] There are authors considering that serum magnesium was significantly low in 
diabetes with complications than in diabetes without complications (p < 0.001). In  
their study, poor glycemic control and the retinopathy were associated with 
hypomagnesaemia. [10] 
Magnesium is cofactor in more than 300 enzymes involved in carbohydrate metabolism, 
required as energy bound, and it activates many enzymes involved in protein and lipids 
metabolism. There are data which show that hypomagnesaemia is associated to, and 
increase insulin resistance and we consider that magnesium can affect cellular action of 
insulin through: the action on the insulin receptor site, by modifying insulin-receptor 
binding, by affecting intracellular transduction of biologic signal; some authors [11] consider 
that Mg could play the role of a second messenger for insulin action by direct action on the 
entrance of glucose into the cell or by action on certain enzymes sites. 
Magnesium deficiency may induce the increase of insulin-resistance in non-diabetic persons. 
[12] Deficiency of this cation can be considered a factor involved in pathogenesis and 
complications of type 2 diabetes mellitus. 
Our data reveal significant differences for plasma zinc in NIDDM group versus the control 
group, for plasma zinc. (Fig. 2) 
 
Diabetes Mellitus – Insights and Perspectives 218 
Zinc homeostasis is disturbed in patients with diabetes mellitus. Serum and intracellular 
zinc were significantly lower in diabetic patients compared to controls and our data are in 
accordance with other authors. [13] The urinary elimination of zinc is increased and 
intestinal absorption is decreased in patients with diabetes mellitus. Imbalances in zinc 
homeostasis with reduced plasmatic levels can determine deficiencies of beta pancreatic 
cells to produce and secrete insulin. The deficit of this cation can affect phosphorylation/ 
dephosphorylation of one or more steps in insulin cell signaling. [14] 
Zinc ions are involved in the neutralization of free radicals and there is increasing evidence 
supporting the role of zinc as an antioxidant that could protect insulin and cells from being 
attacked by free radicals.[15] A possible mechanism of plasma zinc deficiency is due to 
excessive renal loss. Some authors consider that an impaired gastro-intestinal absorption in 
diabetics may also be involved. It is presumed that hyperglycemia may affect the tubular 
transport of zinc. [16] There are some clinical data that showed that zinc deficiency 
increased zinc occurrence of cataract among people with diabetes mellitus. [17] 
Our data reveal an increased plasma level of copper in NIDDM patients when compared to 
healthy subjects. (Fig. 3) These data are in accordance with other studies [18] There are 
authors considering that excess copper is involved in type 2 diabetes mellitus pathogenesis 
and utilization of copper specific carriers may be a prospective therapeutic strategy in 
NIDDM. [19] Determination of plasma calcium in NIDDM patients, before medication, 
reveals non-significant differences compared to healthy subjects. 
For urinary magnesium in NIDDM patients our data show an increased urinary magnesium 
level in NIDDM patients, before medication, when compared to healthy subjects. (Fig. 6) 
Our data are in accordance with other studies [20] that evidenced increased urinary levels of 
magnesium in newly diagnosed patients with type 2 diabetes mellitus. The possible 
mechanism involved in increased urinary magnesium elimination may be due to 
hyperglycemia that induces osmotic diuresis with decreased tubular magnesium 
reabsorption.  
For urinary zinc in NIDDM patients our data reveal an increased urinary zinc level in 
NIDDM patients, before medication, when compared to healthy subjects. (Fig. 7) 
Hyperzincuria has been demonstrated in both type 1 and type 2 diabetes mellitus. The 
urinary elimination of zinc has increased and intestinal absorption has decreased in patients 
with diabetes mellitus. The possible mechanism involved in increased urinary zinc 
elimination may be due to hyperglycemia that induces osmotic diuresis. This fact is 
sustained by data that testified a positive correlation between HbA1c and Zn elimination 
being presumed that hyperglycemia interferes with the active Zn transport in tubular cells. 
[20, 21]  
For urinary copper in NIDDM patients our data showed an increased level before 
medication, when compared to healthy subjects but moderate level when compared to Mg 
and Zn elimination, our patients having no renal disorders. (Fig. 8) 
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Other studies revealed urinary increased levels of copper in diabetic patients with associate 
disorders such as infections and neuropathy. [22] 
Urinary calcium concentration in NIDDM patients has increased before medication, 
compared to healthy subjects, (Fig.9), our data being in accordance with other studies that 
evinced increased urinary levels of calcium in NIDDM patients. [23] 
Determination of intra-erythrocyte total magnesium concentration has revealed a decreased 
concentration of this cation in NIDDM patients, before medication, when compared to 
healthy subjects, (fig. 5), and this is in accordance with other studies that evinced 
intracellular hypomagnesaemia in NIDDM patients without medication and dietary control. 
Insulin resistance in type 2 diabetes mellitus can negatively affect insulin capacity of 
stimulation for intracellular entry for both magnesium and glucose. [24] Intracellular 
magnesium has an important role to modulate insulin action, glucose transport and to 
maintain vascular tonus. Reduced intracellular concentrations of magnesium can determine 
deficiencies of tyrosine-kinase activity from the receptor site, also affecting intracellular 
transduction of biologic signal and insulin resistance in type 2 diabetic patients. [25] 
Magnesium may play the role of second messenger and disturbances in intracellular 
concentrations of this cation may contribute to insulin resistance.  
In NIDDM an inverse correlation between plasma level of magnesium and insulin resistance 
has been determined. [26] Intracellular deficiency in Mg2+ and Mg ATP2 can be a genetic 
factor that predisposes to type 2 diabetes mellitus. It is not clear if magnesium transporters 
TPRMs gene expression is affected in NIDDM patients. [27] Treatment with metformin for 3 
months did not modify significantly the plasma concentration of magnesium, NIDDM 
patients being with hypomagnesaemia. (Fig.1) The causes for the lower magnesium levels 
may be a deficiency in magnesium digestive absorption or an increased elimination. The 
patients’ diet contained approximately 320 mg/day magnesium, while a daily need for adult 
people is about 350- 400 mg/day. Together with those factors, the increased urinary 
elimination of this cation, as it appears in diabetic patients, may be a cause.  
It was proved that a diet with low Mg content increase the risk of NIDDM and the incidence 
of metabolic syndrome. [28, 29, 30] 
An inefficient NIDDM metabolic control could disturb the plasma magnesium levels. 
Extracellular hypomagnesaemia is involved in diabetes vascular complications. [31, 32] 
Magnesium deficiency can increase the risk of vascular complications in diabetes. There are 
data from previous researches that evinced positive correlations between magnesium 
deficiency and oxidative stress with reduced plasmatic antioxidant profile and increased 
lipid oxidation. [33] GSH, a tripeptide containing thiol groups is cofactor of many enzymes 
as it is glutathione peroxidase , Mg2+ being a mandatory cofactor in GSH synthesis as it is in 
all processes involving ATPase, and deficiency in Mg may induce alteration in GSH 
synthesis.  
It was proved that oral magnesium supplementation with MgCl2, 2,5 g daily, increases 
insulin sensitivity and metabolic control in patients with type 2 diabetes mellitus [34] and 
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patients with chronic complications such as retinopathy have decreased levels than the 
patients without this complication. It was proved that a low intake in magnesium increases 
the risk of type 2 diabetes in men and women. Treatment with metformin did not improve 
the plasmatic concentration of magnesium. Our data are in agreement with other authors 
who evinced that plasma levels of Mg have not improved at the same time with metabolic 
control improvement. [35]  
Within experimental research, the metformin restored endothelial function and significantly 
improved NO bioavailability in normal and high-fat fed rats. This supports the concept of 
metformin as a first-line therapeutic drug to treat diabetic patients in order to protect 
against endothelial dysfunction associated with type 2 diabetes mellitus. [36, 37]  
Metformin improved also the endothelial function in patients with metabolic syndrome. The 
type 2 diabetes mellitus patients who received metformin has had statistically significant 
improvement in endothelium-dependent vasodilatation compared to those that received 
placebo. [38] 
Plasma zinc determination in NIDDM patients treated with metformin evinced that there 
were not significant differences compared to the initial moment and when compared to 
control group there are still significant differences.( Fig. 2) 
Many studies revealed a deficiency in this divalent cation in diabetic patients. 
Treatment with metformin did not improve the plasmatic concentration of zinc, patients 
being with hypozincemia.There are data revealing that diabetes is characterized by 
intracellular and extracellular imbalances of zinc. Zinc ions are involved in neutralization of 
ROS and nitrogen species through Cu Zn- SOD enzyme. The deficit of this cation can alter 
the antioxidant activity of the enzyme Cu Zn- SOD together with the expression and activity 
of other antioxidant biologic components, moreover, zinc deficiency can increase the 
fractions with oxidant activity such as ROS and RNA, and as consequence, the oxidant 
activity on the tissues, with oxidative capacity on the DNA, proteins and lipids. Imbalances 
in zinc metabolism can be involved in NIMMD pathogenesis and complications. [39] 
Recent data revealed that zinc supplementation is associated with a decreased risk of 
diabetes appearance in women. [40] For short periods, zinc supplementation can improve 
the plasma glucose level in diabetic patients with increased values of HbA1c and decreased 
levels of zinc. [41]  
A place in type 2 diabetes pathogenesis and complications is assigned to zinc transporter 
proteins (Zn Ts) and to metallothioneins (MTs). Many authors consider that a change in sub-
cellular distribution of those may be more important than the deficiency in zinc, and those 
should be considered a future therapeutic target in diabetes.[42] There are some clinical data 
showing that zinc deficiency increased occurrence of cataract among people with diabetes 
mellitus. [17] Zinc and magnesium concentrations decreased in experimentally induced 
diabetes in rats [43]. 
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The effect of zinc supplementation in the treatment of diabetes mellitus is controversial. 
[44] There is no evidence to suggest the use of zinc supplementation in the prevention of 
type 2 diabetes mellitus [45], but there are studies which suggest that zinc and 
magnesium supplementation might ameliorate diabetic neuropathy symptoms.[46] 
Treatment with metformin did not significantly modify the concentration of copper, but 
when we compare those levels between the metabolic uncontrolled patients and the ones 
with metabolic control of metformin treatment we see that there are significant 
differences. There are data revealing that increased levels of copper are not influenced by 
metabolic control [47]. Diabetes mellitus is a chronic metabolic disorder, which is 
associated with the increased free radical production leading to oxidative damage: the 
oxidative stress and copper both have pro-oxidant effects. This cation catalyzes the 
oxidative modification of LDL, in vitro and in the arterial wall and the presence of 
copper in high concentration can facilitate the production of free radicals through Fenton 
reaction [48]. 
The decrease of serum copper is associated to the decrease of the production of ROS on the 
animals with experimental diabetes. We believe that the excess of copper is involved in the 
pathogenesis of some complications of NIDDM. Plasma calcium determination in diabetic 
patients treated with metformin had showed that there were no significant differences 
compared to the initial moment. Intra-erythrocyte magnesium in NIDDM patients treated 
with metformin revealed that there were significant differences compared to the moment 
before medication. (Fig. 5) The results are in accordance with our previous data [49] and 
with few other results that revealed an increased tissue levels of magnesium associated with 
metformin treatment. [50] However, our study revealed there is still a decreased intra-
erythrocyte magnesium level when compared to the control group. There are data revealing 
that hypomagnesaemia is associated to and increases insulin resistance. [26] Low levels of 
magnesium are associated to the increase of insulin-resistance in non-diabetic subjects as 
well. Treatment with metformin improved the intracellular concentration of this cation, due 
probably to the mechanism of action of this biguanide drug that improves the peripheral 
action of insulin, through an increase of GLUT 4 transporters on the plasmatic membrane, 
magnesium having insulin-like functions. Metformin is a drug that increases the glucose 
transport. Within other studies, intracellular magnesium increased after following treatment 
with rosiglitazone but metformin had no effect on intracellular calcium or magnesium. Ca 
and Mg were assessed in PBMC from healthy subjects following 72h in vitro treatment with 
the respective drugs and calcium content increased significantly. [51] Metformin 
administration improved Na(+)K(+)ATPase activity (0.28±0.08, 0.41±0.07μmol Pi/mg/h) in 
erythrocyte membrane, but is not clear if this action can influence bivalent cations 
intracellular concentrations. [52] 
Metformin also improved the endothelial function in patients with metabolic syndrome. The 
type 2 diabetes mellitus patients who received metformin had statistically significant 
improvement in endothelium-dependent vasodilatation compared to those that received 
placebo. [53] We think that, in part, the endothelium protective effect of metformin is not 
produced only by NO way, but also by increasing the magnesium intracellular 
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concentration. Good magnesium status is associated with reduced diabetes risk. The 
average glucose-lowering effect of the major classes of oral anti-diabetic agents is broadly 
similar, but the influence on the various bivalent cations concentrations and on vascular 
endothelium is not. Our study revealed an improvement of intra-erythrocyte magnesium by 
metformin medication without an improvement of plasmatic magnesium. Metformin 
medication improved the urinary elimination of magnesium (Fig. 6), results that are in 
accordance with other researchers that revealed an improvement of this cation elimination 
[23] but compared to the control group the diabetic patients still have hypermagnesemia. 
We suppose that the decreased urinary elimination of magnesium may be due to the 
decreased in plasma glycemia by use of metformin as well as a possible action of this drug 
on the renal cation transporters. 
Treatment with metformin did not modify zinc elimination, patients with diabetes mellitus 
type 2 having hyperzincuria. (Fig. 7) The urinary elimination of zinc is increased and 
intestinal absorption is decreased in patients with diabetes mellitus. There are some research 
data confirming that patients with type 1 and type 2 diabetes mellitus have increased levels 
of zinc concentration in urine. [54] Increased urinary levels of this cation can be involved in 
the plasmatic reduced levels, and the mechanism involved may be due to hyperglycemia 
that can interfere with the Zn transport back in renal tubular cells, but we cannot exclude 
other interventions of zinc ions on the zinc transporters. 
Metformin administration did not significantly modify the urinary elimination of copper 
when comparing the metabolic uncontrolled group of metformin administration and the 
group controlled by medication, there are significant differences. (Fig. 4) 
Metformin administration for 3 months did not significantly modify the urinary elimination 
of calcium but compared to the control group there are still significant differences, diabetic 
patients being with hypercalciuria. (Fig. 9) 
The negative correlation between plasma Mg and plasma glucose level in patients treated 3 
months with metformin revealed that the treatment with metformin did not improve the 
plasma levels of magnesium, but increased the intracellular magnesium concentration. 
The negative correlation between plasma magnesium and HbA1c evidenced the fact that the 
metabolic uncontrolled patients through medication have low levels of magnesium.  
Our data are in accordance with other authors that revealed an inverse correlation between 
the metabolic control of NIDDM and plasma hypomagnesaemia. [32] 
There are authors suggesting that the diabetes itself can induce hypomagnesaemia, while 
others revealed the fact that a supplementation of Mg can reduce the risk of development of 
type 2 diabetes mellitus and can improve the insulin sensitivity. [55] Our data indicated a 
low intracellular magnesium concentration in NIMMD patients and an increase of intra-
erythrocyte magnesium after metformin treatment. This is an important point in metformin 
action because magnesium deficiency promotes the development of dyslipidemia and the 
atherogenesis. [56]  
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The increased oxidative stress in diabetes mellitus contribute to the development of diabetic 
macrovascular and microvascular complications through increased lipid oxidation, 
especially by increasing oxidation of LDL, which is a crucial step in the development of 
atherosclerosis. Magnesium can reduce the oxidative stress [57] and we consider that this is 
an important mechanism for antiatherogenic action of certain antidiabetes drugs. 
Our results are in accordance with other authors that evinced positive correlations between 
plasma Cu and glycemia. [58] Once again it is proved that there is a disbalance in the copper 
ions in diabetes type 2 and once proved the implications of these cations in the pathogenesis 
and complications of diabetes. 
The positive correlation between plasma copper and cholesterol, tryglicerides concentration 
confirms the fact that increased levels of copper are associated with lipid metabolism 
disturbances.The involvement of copper ions in plasma lipids metabolism are controversial. 
Various studies proved inverse correlations between low dietary copper and cholesterol and 
LDL cholesterol, in both: human and rats, and in rats with low copper diet HDL cholesterol 
had increased. [59]  
Treatment with metformin did not modify the urinary loss nor the plasma decreased levels, 
all of those implying the hyperglycemia as factor involved. The issue of the correlation 
between copper, zinc and magnesium status and complications of diabetes mellitus is an 
open one. In other studies it was reported an increased plasma copper concentration in 
patients with specific diabetes associated complications (retinopathy, microvascular diseases 
or arterial hypertension) [60, 61] but no significant differences between control and diabetic 
patients in erythrocyte copper-zinc superoxide dismutase. The relationship between 
coronary risk factors in NIDDM patients is also extremely important. The plasma 
zinc/copper ratio is inversely associated with calculated 10 years coronary risk in non-
diabetic patients. [62] 
6. Conclusions 
Our data are in accordance with those of other authors [32] that revealed an inverse 
correlation between the metabolic control of NIDDM and low plasma magnesium level.  
Negative correlation between erythrocyte magnesium and HbA1c evinced that low 
metabolic control by medication is associated with intracellular deficit of magnesium. In our 
opinion, the intracellular magnesium concentration plays a more important role in 
prevention of the development of hypercholesterolemia and atherogenesis than plasma 
level of this cation. 
Metformin did not modify the plasma levels of copper. About the risk for the development 
of vascular complication of patients with type 2 diabetes, we believe that the ratio between 
the concentrations of intracellular magnesium +serum zinc/serum copper is a good marker 
for the risk of diabetes complications development. A higher ratio indicates a more reduced 
risk and a low ratio an increased risk. In the evaluation of the antidiabetic effect of certain 
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drugs must be to keep account of their influence on magnesium, zinc and copper plasma 
and intracellular concentrations. 
We consider that magnesium and zinc administration can be of benefit in type 2 diabetes 
mellitus .The copper chelators could represent also a future medication in diabetes. 
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